This early-stage study is testing a new combination of three drugs for people whose non-Hodgkin's lymphoma has come back after prior treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and …
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC